abietanetyp
diterpenoid
ferruginol
bioactiv
compound
isol
sever
plant
attract
much
attent
consequ
pharmacolog
properti
includ
antibacteri
antifung
antimicrobi
cardioprotect
antioxid
antiplasmodi
leishmanicid
antiulcerogen
antiinflammatori
antitumor
action
studi
report
antivir
evalu
ferruginol
sever
analogu
synthes
commerci
dehydroabietylamin
thu
activ
human
herpesviru
type
human
herpesviru
type
dengu
viru
type
studi
two
ferruginol
analogu
show
high
antivir
select
index
reduc
viral
plaques
postinfect
stage
herp
dengu
virus
promis
lead
compound
tenfold
potent
ec
mm
control
ribavirin
dengu
viru
type
find
suggest
skeleton
characterist
diterpenoid
ferruginol
interest
molecular
scaffold
develop
novel
antivir
addit
cytotox
antifung
activ
synthes
ferruginol
analogu
also
investig
human
herpesviru
hhv
type
envelop
dna
virus
character
produc
latent
infect
sensori
neuron
reactiv
period
sever
immunosuppress
host
mani
factor
stress
fatigu
sexual
relat
peopl
activ
lesion
excess
exposur
heat
cold
fever
laser
treatment
local
tissu
trauma
nerv
damag
predispos
reactiv
especi
neonat
transplant
immunocompromis
patient
tend
present
aggress
recurr
lesion
also
report
prolong
therapi
acyclovir
acv
analogu
induc
emerg
drugresist
viru
strain
human
herpesviru
predominantli
develop
resist
almost
result
mutat
gene
encod
viral
thymidin
kinas
tk
howev
mutat
viral
dna
polymeras
also
caus
resist
immunocompromis
patient
presenc
hhv
speci
resist
acv
preval
complic
clinic
manag
moreov
dengu
viru
denv
envelop
ssrna
viru
date
describ
four
serotyp
establish
human
recent
fifth
dengu
subtyp
follow
sylvat
cycl
identifi
dengu
import
mosquitoborn
diseas
worldwid
sinc
distribut
one
hundr
countri
tropic
belt
tropic
old
new
world
diseas
manifest
cover
wide
spectrum
rang
dengu
without
warn
sign
sever
dengu
plasma
leakag
haemorrhag
organ
impair
lead
death
addit
unusu
manifest
cardiomyopathi
liver
failur
neurolog
disord
report
major
problem
patholog
drug
approv
human
treatment
vaccin
avail
prophylaxi
also
antivir
drug
address
specif
gene
protein
viru
good
altern
due
high
mutat
rate
rna
virus
often
viral
mutant
select
drug
resist
last
year
colombia
sever
report
shown
high
rate
evolut
denv
possibl
relat
new
asiaticamerican
genotyp
found
colombia
brazil
aromat
abietanetyp
diterpenoid
compris
larg
number
natur
metabolit
plant
origin
possess
wide
varieti
biolog
effect
abietan
target
sever
synthet
campaign
toward
natur
product
synthet
deriv
interest
pharmacolog
properti
among
known
bioactiv
compound
ferruginol
deriv
dehydroabiet
acid
dehydroabietylamin
well
jiadifeno
acid
c
fig
shown
promis
result
includ
antivir
properti
present
studi
continu
research
program
discov
bioactiv
diterpenoid
includ
synthesi
focus
librari
base
ferruginol
commerci
avail
dehydroabietylamin
seri
phthalimid
could
potenti
antivir
activ
fulleren
diterpenoid
hybrid
also
envisag
potenti
inhibitor
herein
describ
antivir
activ
ferruginol
analogu
scheme
synthes
dehydroabietylamin
aim
identifi
new
antivir
drug
candid
act
cellular
andor
molecular
target
instead
viral
protein
way
concern
viral
mutant
resist
treatment
avoid
approach
recent
call
hosttarget
antivir
evolutionari
studi
resist
dengu
virus
select
pressur
sever
antivir
agent
synthesi
ferruginol
analogu
commerci
dehydroabietylamin
perform
outlin
scheme
compound
synthes
report
literatur
use
friedelecraft
acyl
baeyerevillig
oxid
key
step
compound
use
start
materi
prepar
compound
later
compound
convert
compound
describ
recent
literatur
thu
synthesi
start
introduct
phthalimid
group
dehydroabietylamin
follow
friedelecraft
acyl
oxid
baeyervillig
condit
afford
acet
overal
yield
hydrolysi
acet
group
gave
phenol
high
yield
overal
deprotect
afford
aminophenol
yield
compound
intermedi
three
separ
approach
firstli
tosyl
standard
condit
gave
compound
yield
secondli
oxid
deamin
gave
moder
yield
convert
ferruginol
wolffkishn
reduct
yield
final
treatment
tetrachlorophthal
anhydrid
tcpa
afford
phenol
yield
acetyl
acet
anhydrid
pyridin
give
acet
quantit
yield
acet
oxid
excess
tbuooh
oxid
cro
pyridin
mixtur
catalyst
dcm
yield
keton
subsequ
reaction
ptosylhydrazid
yield
correspond
ptosylhydrazon
yield
fullereneterpenoid
hybrid
obtain
treatment
naom
anhydr
pyridin
min
room
temperatur
follow
addit
solut
c
chlorobenzen
heat
c
h
gave
compound
ca
yield
compound
show
spectroscop
data
agreement
assign
structur
puriti
synthes
compound
scheme
evalu
antivir
activ
see
tabl
two
ferruginol
analogu
compound
show
relev
activ
particular
ferruginol
analogu
show
moder
activ
rf
concentr
mm
high
activ
rf
reduct
cytopath
effect
infect
compar
control
untreat
cell
concentr
mm
compound
also
show
high
activ
rf
concentr
mm
howev
abil
exert
reduct
cytopath
effect
presenc
infect
lower
compound
moreov
compound
show
activ
wen
cowork
report
antivir
potenti
certain
diterpenoid
deriv
includ
abietanetyp
diterpenoid
ferruginol
vitro
coronaviru
infect
howev
present
antivir
activ
abietan
class
compound
much
investig
especi
studi
deriv
analogu
therefor
activ
report
studi
knowledg
first
report
antivir
activ
ferruginol
analogu
also
compound
activ
two
differ
virus
herpesviru
dengu
viru
find
suggest
molecul
probabl
broadspectrum
antivir
activ
envelop
virus
dna
rna
genom
later
check
specif
antivir
activ
compound
carri
evalu
biolog
activ
cytotox
antifung
well
known
ferruginol
promis
bioactiv
antifung
antibacteri
miticid
antiplasmodi
antileishmani
nematicid
antitumor
among
other
tabl
shown
cytotox
activ
vero
cell
well
tumor
cell
hela
jurkat
ferruginol
analogu
addit
antifung
activ
compound
studi
two
dermatophyt
trichophyton
rubrum
trichophyton
mentagrophyt
filament
fungi
fusarium
oxysporum
aspergillu
fumigatu
aspergillu
flavu
aspergillu
terreu
one
ferruginol
analogu
compound
show
antidermatophyt
activ
rubrum
mentagrophyt
geometr
scheme
synthesi
test
compound
tabl
reduct
viral
titer
inhibit
cytopath
effect
antivir
activ
ferruginol
analogu
although
sever
studi
show
ferruginol
relat
abietan
exhibit
promis
antifung
cytotox
activ
result
reveal
compound
lack
antifung
activ
fungal
model
test
cytotox
hela
jurkat
tumor
cell
evalu
concentr
therefor
compound
could
select
molecul
envelop
virus
previou
studi
suggest
mechan
ferruginol
exert
antitumor
activ
relat
enhanc
express
bax
proapoptot
protein
inhibit
signal
pathway
involv
cell
surviv
prolifer
ra
jakstat
reduct
express
cyclindepend
kinas
howev
cellular
molecular
basi
compound
exhibit
antivir
activ
current
describ
order
defin
stage
viral
replic
cycl
ferruginol
analogu
activ
perform
two
differ
condit
treatment
firstli
test
effect
compound
earli
stage
viral
replic
cycl
cellfre
viral
particl
adhes
viral
entri
treatment
infect
preinfect
treatment
secondli
test
antivir
activ
sever
step
viral
cycl
includ
traffic
replic
assembl
egress
new
viral
particl
celltocel
spread
treatment
infect
postinfect
treatment
seen
tabl
compound
effect
postinfect
treatment
activ
preinfect
treatment
preand
postinfect
treatment
plaqu
reduct
assay
perform
concentr
compound
reduc
number
viral
plaqu
ec
interpol
doseerespons
curv
furthermor
antivir
select
index
si
calcul
relat
inhibitori
concentr
ic
vero
cell
ec
viru
ic
ec
tabl
compound
reduc
plaqu
form
unit
concentr
mm
show
high
si
equal
wherea
compound
reduc
number
plaqu
concentr
mm
mm
respect
expect
control
dex
acv
show
antivir
activ
pretreat
posttreat
respect
result
show
compound
import
activ
strain
low
concentr
comparison
possibl
due
smaller
number
receptor
avail
host
cell
carri
infect
make
viru
sensit
action
compound
differ
activ
compound
found
strain
endpoint
titrat
techniqu
eptt
assay
compound
show
moder
activ
tabl
rf
plaqu
form
unit
pfu
assay
compound
show
dosedepend
effect
howev
show
signific
reduct
viral
plaqu
size
tabl
highlight
asterisk
relat
among
other
low
rate
viral
replic
reduct
cytopath
effect
confirm
antivir
effect
compound
hand
compound
show
reduct
viral
titer
screen
eptt
inhibit
number
plaqu
form
unit
pfu
assay
differ
explain
due
amount
viru
use
assay
eptt
assay
high
amount
viru
tcid
use
concentr
compound
show
antivir
activ
could
detect
pfu
assay
pfuwel
use
ec
valu
determin
nevertheless
compound
show
high
si
valu
demonstr
close
cytotox
concentr
antivir
concentr
likewis
antidengu
activ
ferruginol
analogu
evalu
day
postinfect
dpi
compound
antivir
select
index
defin
rel
effect
product
inhibit
viral
replic
compar
capac
induc
cell
death
index
result
use
make
bioactiv
comparison
compound
help
design
potent
compound
recent
report
si
valu
higher
si
consid
indic
potenti
therapeut
agent
would
merit
biopharmaceut
preclin
studi
therefor
compound
promissori
continu
type
studi
addit
dosedepend
effect
previous
describ
postinfect
treatment
found
compound
induc
reduct
viral
plaqu
size
determin
averag
reduct
viral
plaqu
size
compoundtreat
rel
mocktreat
control
perform
imag
analysi
use
imagepro
plu
softwar
fig
area
plaqu
measur
millimet
statist
signific
differ
p
valu
found
case
compound
show
dramat
reduct
viral
plaqu
size
concentr
mm
cdcatlanta
acyclovirsensit
strain
fig
respect
compound
reduc
size
viral
plaqu
concentr
mm
fig
furthermor
treatment
compound
concentr
mm
fig
cell
infect
acyclovirresist
strain
thymidin
kinas
mutant
found
similar
effect
show
acyclovirsensit
strain
reduc
viral
plaqu
size
find
may
suggest
phosphoryl
viral
thymidin
kinas
requir
effect
exert
compound
thu
possibl
antiherpet
mechan
action
ferruginol
analogu
differ
acyclovir
nucleosid
analogu
likewis
reduct
viral
plaques
observ
cell
infect
treat
compound
concentr
mm
fig
reduct
percentag
report
virus
indic
reduct
viral
plaqu
size
compoundtreat
rel
mocktreat
control
represent
plaqu
morpholog
cdc
atlanta
treatment
compound
mocktreat
control
shown
figur
f
respect
fig
show
effect
treatment
compound
mocktreat
control
reduct
viral
plaqu
size
hhv
strain
presenc
compound
suggest
ferruginol
analogu
may
prevent
firstround
viral
replic
releas
andor
celltocel
spread
last
stage
import
factor
infect
virul
establish
latenc
immun
respons
evas
herpesviru
infect
therefor
inhibit
viral
intercellular
diffus
attract
target
search
new
antivir
drug
mainli
treat
latent
infect
drugresist
strain
recent
year
sever
compound
shown
effect
viru
celltocel
spread
herpesviru
infect
exampl
lin
cowork
report
chebulag
acid
punicalagin
two
hydrolyz
tannin
isol
terminalia
chebula
combretacea
inhibit
celltocel
spread
fact
verifi
h
posttreat
use
fluoresc
plaqu
assay
presenc
neutral
antibodi
guarante
celltocel
transmiss
via
intercellular
junction
infect
uninfect
cell
meanwhil
nyberg
ekblad
cowork
demonstr
low
molecular
weight
heparin
sulfatemim
mixtur
highli
sulfat
mannos
contain
oligosaccharid
reduc
area
viral
plaqu
ic
valu
mgml
mgml
respect
nevertheless
date
report
similar
effect
viral
plaqu
size
hhv
virus
abietan
diterpenoid
among
ferruginol
deriv
sever
molecular
cellular
compon
involv
herpesviru
celltocel
spread
previous
report
exampl
viral
glycoprotein
e
play
relev
role
normal
viral
plaqu
phenotyp
plaqu
size
doubledelet
mutant
dgegm
reduc
less
wild
type
strain
polar
epitheli
cell
johnson
cowork
demonstr
electron
microscopi
gegi
glycoprotein
complex
necessari
accumul
virion
cell
junction
sinc
mutant
express
ge
glycoprotein
lead
particl
accumul
frequent
apic
surfac
thu
conclud
gegi
complex
requir
sort
select
particl
later
surfac
specif
cell
junction
hand
structur
contain
actin
tubulin
herpesvirus
infect
abil
project
virion
toward
adjac
cell
addit
membran
composit
cytoskelet
structur
egress
site
modifi
infect
nonpolar
cell
accord
find
dixit
cowork
also
promot
cytoskelet
rearrang
facilit
viral
spread
vitro
includ
dramat
increas
filopodia
cultur
neuron
multipl
converg
way
sever
virus
vaccinia
hepat
b
c
virus
human
immunodefici
viru
human
tlymphotrop
viru
murin
leukemia
viru
hhv
caus
subvers
cytoskeleton
differ
object
viral
cycl
summar
taylor
cowork
actin
cytoskeleton
reorgan
virus
affect
everi
stage
viral
life
cycl
entri
assembl
egress
use
immunochem
assay
drug
inhibit
assay
protein
interact
profil
method
wang
cowork
identifi
way
interact
actin
cytoskeleton
studi
show
dynam
treadmil
actin
necessari
dengu
viru
entri
product
releas
indic
direct
effect
viral
e
protein
structur
modif
actin
cytoskeleton
consid
cytoskelet
compon
microtubul
actin
microfila
requir
herpesviru
flaviviru
replic
cycl
mainli
involv
entri
traffic
releas
celltocel
spread
possibl
ferruginol
analogu
caus
disrupt
cellular
pathway
may
involv
viral
spread
nonetheless
experi
requir
confirm
hypothesi
although
riski
assur
viral
cellular
compon
involv
find
studi
ferruginol
analogu
import
tool
medicin
chemistri
dissect
complic
cellular
molecular
process
viral
infect
futur
research
rout
understand
cellular
molecular
mechan
two
differ
virus
herpesviru
dengu
converg
conserv
evolutionari
pathway
cell
infect
affect
cytoskeleton
element
endomembran
system
signal
pathway
involv
viral
egress
hostcel
spread
infect
toward
neighbor
cell
summari
discov
import
antivir
properti
molecular
scaffold
function
reminisc
abietan
diterpenoid
ferruginol
two
ferruginol
analogu
compound
synthes
readili
avail
dehydroabietylamin
found
consist
inhibit
human
herpesviru
type
dengu
viru
type
low
micromolar
concentr
compound
show
antivir
activ
specif
postinfect
stage
significantli
reduc
viral
plaques
infect
presenc
phthalimid
moieti
molecul
compound
result
highest
antivir
select
index
virus
test
tenfold
potenc
ec
mm
control
ribavirin
dengu
viru
type
regard
cytotox
properti
test
compound
note
chlorinatedphthalimid
analogu
exhibit
moder
cytotox
broad
spectrum
without
toxic
toward
nontumor
cell
line
vero
addit
test
compound
show
relev
antifung
activ
base
result
report
relev
research
possibl
cellular
molecular
mechan
involv
effect
reduct
viral
plaqu
size
also
find
import
promot
realiz
biopharmaceut
test
find
new
highli
select
antivir
drug
mainli
direct
toward
cellular
target
optic
rotat
measur
use
cm
cell
schmidthaensch
polartronicd
polarimet
nmr
spectra
record
mhz
spectromet
spectra
record
cdcl
solvent
unless
otherwis
state
complet
assign
c
nmr
multipl
made
basi
dept
experi
j
valu
given
hz
ms
data
acquir
qtof
spectromet
reaction
monitor
tlc
use
merck
silica
gel
mmthick
plate
compound
tlc
plate
detect
uv
light
nm
visual
immers
sulfur
acid
solut
heat
heat
gun
purif
perform
flash
chromatographi
merck
silica
gel
mesh
commerci
reagent
grade
solvent
chemic
use
purchas
unless
otherwis
note
combin
organ
extract
wash
brine
dri
anhydr
naso
filter
concentr
reduc
pressur
compound
prepar
accord
known
procedur
compound
use
start
materi
prepar
compound
later
compound
convert
compound
describ
recent
literatur
compound
prepar
work
exhibit
spectroscop
data
agreement
propos
structur
puriti
final
compound
higher
n
tetrachlorophthaloyl
dehydroabietylamin
mixtur
tetrachlorophthal
anhydrid
mg
mmol
mg
mmol
acet
acid
ml
heat
reflux
h
cool
rt
ml
water
ad
result
solid
filter
wash
water
dri
vacuum
purifi
column
chromatographi
elut
toluen
give
compound
solut
phenol
mg
mmol
mixtur
ml
acet
anhydrid
pyridin
stir
rt
one
day
ml
water
ad
mixtur
extract
ethyl
acet
ml
combin
organ
extract
wash
nahco
ml
water
brine
result
organ
extract
dri
sodium
sulfat
filter
concentr
residu
chromatograph
silica
elut
chloroform
afford
acet
mg
white
solid
ident
spectroscop
data
report
literatur
dulbecco
modifi
eagl
medium
dmem
tetrazolium
bromid
mtt
obtain
sigmaealdrich
chemic
co
st
loui
mo
usa
fetal
bovin
serum
fb
penicillinstreptomycin
purchas
invitrogen
life
technolog
carlsbad
ca
usa
acyclovir
obtain
biogen
laboratori
ribavirin
obtain
calbiochem
la
jolla
ca
usa
paclitaxel
doxorubicin
amphotericin
b
itraconazol
purchas
sigmaealdrich
chemic
co
terbinafin
obtain
recalcin
laboratori
santiago
de
chile
chile
dimethyl
sulfoxid
dmso
purchas
merck
kgaa
darmstadt
germani
stock
solut
compound
prepar
dmso
frozen
c
concentr
dmso
biolog
assay
cell
control
dmso
use
human
herpesviru
type
cdc
atlanta
acyclovirsensit
strain
obtain
center
diseas
control
atlanta
ga
usa
acyclovirresist
strain
donat
prof
claudia
oliveira
univers
santacatarinabrazil
human
herpesviru
type
acyclovirsensit
strain
obtain
center
diseas
control
amplifi
vero
cell
african
green
monkey
kidneycercopithecu
aethiop
atcc
ccl
line
viru
stock
titrat
vero
cell
plaqu
assay
express
plaqu
form
unit
pfuml
dengu
viru
type
new
guinea
strain
donat
maria
elena
eva
harri
sustain
scienc
institut
univers
california
berkeley
amplifi
aed
albopictu
cell
atcc
titrat
vero
cell
follow
laboratori
condit
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
inactiv
fb
vero
cell
inactiv
fb
cell
unitsml
penicillin
mgml
streptomycin
mgml
lglutamin
nahco
nonessenti
amino
acid
minimum
essenti
medium
vitamin
solut
cholin
chlorid
dcalcium
pantothen
folic
acid
nicotinamid
pyridox
hydrochlorid
riboflavin
thiamin
hydrochlorid
iinositol
vero
cell
incub
c
humidifi
co
atmospher
ht
c
humidifi
co
atmospher
antiherpet
activ
ferruginol
analogu
vero
cell
tcid
carri
use
endpoint
titrat
techniqu
eptt
vero
cell
harvest
plate
densiti
cellswel
c
humidifi
co
atmospher
constitut
cell
monolay
viral
suspensioncompound
mixtur
perform
dmem
fb
supplement
contain
carboxymethylcellulos
cmc
respect
incub
min
room
temperatur
compound
evalu
concentr
mgml
h
h
incub
c
humidifi
co
atmospher
cell
monolay
stain
solut
formaldehyd
crystal
violet
plaqu
count
two
independ
experi
quadrupl
carri
viral
serotyp
compound
control
includ
untreat
cell
cell
treat
compound
cell
infect
posit
control
includ
assay
acyclovir
accord
paramet
establish
vlietinck
et
al
relev
moder
antivir
activ
purifi
natur
product
one
whose
reduct
factor
rf
viral
titer
respect
paramet
use
studi
determin
antidenv
activ
carri
protocol
previous
describ
tang
et
al
modif
briefli
vero
cell
harvest
plate
densiti
cellswel
c
humidifi
co
atmospher
h
medium
remov
twofold
serial
dilut
noncytotox
concentr
compound
incub
min
room
temperatur
ml
dilut
ad
plate
incub
c
day
time
cytopath
effect
cpe
control
infect
cell
observ
cell
monolay
cell
monolay
stain
solut
formaldehyd
crystal
violet
cpe
observ
invert
microscop
control
includ
untreat
cell
cell
treat
compound
cell
infect
posit
control
use
ribavirin
compound
consid
activ
abil
reduc
avoid
cytopath
effect
viral
infect
assay
conduct
quadrupl
repeat
twice
compound
subsequ
potenti
antivir
activ
compound
evalu
plaqu
reduct
assay
previous
describ
vero
cell
monolay
grown
plate
cell
well
infect
pfu
per
well
viru
treatment
perform
ad
compound
either
simultan
viru
preinfect
treatment
viral
infect
postinfect
treatment
preinfect
treatment
viruscompound
mixtur
ad
cell
monolay
incub
h
c
co
incub
wash
perform
pb
ph
ad
cmc
respect
postinfect
treatment
viru
ad
cell
monolay
incub
h
c
co
wash
perform
pb
ph
compound
previous
prepar
cmc
respect
ad
treatment
plate
allow
incub
h
day
cell
fix
stain
solut
formaldehyd
crystal
violet
viral
plaqu
count
dextran
sulfat
employ
posit
control
preinfect
assay
ayclovir
acv
ribavirin
riba
use
posit
control
postinfect
stage
hhv
strain
respect
fifti
effect
concentr
ec
defin
concentr
reduc
plaqu
form
unit
ec
compound
obtain
doseeeffect
curv
linear
regress
method
use
statist
graphpad
prisma
ec
valu
express
mean
least
four
dilut
quadrupl
defin
compound
select
infect
cell
noninfect
cell
antivir
select
index
si
calcul
defin
ratio
inhibitori
concentr
ic
vero
cell
ec
viru
vero
cell
pfu
assay
carri
vero
cell
cellswel
compound
previous
prepar
cmc
ad
h
infect
pfuwel
viru
compound
ad
concentr
mgml
mgml
compound
concentr
mgml
mgml
cdcatlanta
determin
effect
compound
ad
concentr
rang
mgml
mgml
final
plate
incub
h
hhv
strain
day
fix
stain
solut
crystal
violet
imag
plaqu
compound
concentr
well
captur
use
nikon
digit
camera
view
attach
nikon
invert
microscop
tokyo
japan
area
plaqu
millimet
determin
use
imagepro
plu
softwar
two
independ
experi
perform
duplic
cell
growth
inhibit
andor
cytotox
vero
hela
jurkat
cell
measur
use
techniqu
mtt
mtt
bromid
sigma
new
jersey
usa
assay
accord
protocol
previous
describ
modif
use
briefli
vero
hela
cell
plate
cell
per
well
flatbottom
plate
incub
h
c
moreov
jurkat
cell
plate
cell
per
well
roundbottom
plate
dilut
compound
ad
appropri
well
plate
incub
h
c
humidifi
incub
co
final
spectrophotometr
read
carri
nm
determin
inhibitori
concentr
ic
defin
concentr
compound
inhibit
cell
growth
ic
valu
compound
obtain
linear
regress
analysi
doseerespons
curv
gener
absorb
data
statist
graphpad
prisma
ic
valu
express
geometr
mean
two
independ
experi
done
quadrupl
defin
compound
select
cancer
cell
noncancer
cell
calcul
select
index
si
defin
vero
ic
hela
jurkat
ic
compound
ic
mm
consid
activ
si
consid
select
paclitaxel
doxorubicin
use
posit
control
vitro
antifung
activ
compound
evalu
follow
clinic
laboratori
standard
institut
protocol
filament
fungi
modif
standard
method
propos
antifung
suscept
test
subcommitte
european
committe
antibiot
suscept
test
afsteucast
yeast
filament
fungi
f
oxysporum
atcc
fumigatu
atcc
flavu
atcc
terreu
cdc
dermatophyt
rubrum
atcc
mentagrophyt
atcc
use
evalu
antifung
activ
inoculum
size
cfuml
yeast
c
albican
atcc
c
parapsilosi
atcc
c
tropicali
atcc
use
evalu
antifung
activ
inoculum
size
cfuml
dilut
compound
dispens
flatbottom
microdilut
plate
duplic
final
concentr
mgml
mgml
compound
consid
activ
exhibit
mic
valu
mgml
clsi
method
mic
defin
lowest
dilut
result
inhibit
visibl
growth
incub
c
h
f
oxysporum
day
dermatophyt
amphotericin
b
evalu
rang
mgml
strain
fumigatu
atcc
flavu
atcc
terbinafin
use
posit
control
rang
mgml
dermatophyt
afsteucast
method
mic
determin
h
incub
c
defin
lowest
concentr
result
reduct
growth
itraconazol
use
posit
control
final
concentr
mgml
neg
control
inoculum
without
treatment
also
includ
mic
valu
express
geometr
mean
gmmic
test
perform
duplic
three
differ
assay
fungi
speci
